{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"116","value":"171"},{"groupId":"OG002","spread":"99","value":"354"},{"groupId":"OG003","spread":"41","value":"248"},{"groupId":"OG004","spread":"73","value":"1260"},{"groupId":"OG005","spread":"29","value":"1139"},{"groupId":"OG007","spread":"158","value":"63.5"},{"groupId":"OG008","spread":"169","value":"177"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"12"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"105","value":"125"},{"groupId":"OG002","spread":"1541","value":"59.6"},{"groupId":"OG007","spread":"144","value":"66.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"12"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Schedule A: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.045 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Schedule A: IMGN632 0.045 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.09 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Schedule A: IMGN632 0.09 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.18 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Schedule A: IMGN632 0.18 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.3 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Schedule A: IMGN632 0.3 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.45 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Schedule A: IMGN632 0.45 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG006","title":"Schedule B: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.03 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG007","title":"Schedule B: IMGN632 0.03 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.06 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG008","title":"Schedule B: IMGN632 0.06 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who received at least 1 dose of study drug and from whom results of concentration had been obtained at least 1 sampling point. PK data were collected and analyses were conducted in participants per treatment schedule and dose in both phases (dose escalation and expansion) combined. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and Cycle 3 (each cycle length = 21 days)","title":"AUC0-last of FGN849","type":"SECONDARY","unitOfMeasure":"hours*pg/mL"}